Table 3.

Characteristics of non-responders at four weeks after the second dose.

Diagnosis n (%)	Ongoing therapy	Age mean ± SD (range)	Gender n (%)	Vaccine n (%)
SOT: (lung cancer) 1 (7.7)	chemotherapy	71 years	female	BNT162b2
MM:	either anti CD38, alkylating agents, thalodimide analogues, JAK inhibitors, cytostatic, proteasome inhibitors, steroids or a combination thereof; n=1 without ongoing treatment	73.4 years	female: 7 (58.3)	BNT162b2: 11 (91.7)
12 (92.3) (of those 4 (33.3) with stem cell transplantation)		± 6.5; (57 – 83)	male: 5 (41.7)	mRNA-1273: 1 (8.3)

Clinical and demographic parameters of those 13 patients with negative antibody responses measured at four weeks after the second vaccine dose.